

PD Dr. med. Christina Mitteldorf

Klinische Tätigkeit:

- Dermatohistologie
- Dermatoonkologie
- Lymphome und Pseudolymphome der Haut
- Allgemeine Dermatologie

Forschungsschwerpunkt:

- Kutane Lymphome und Pseudolymphome
- Tumorbiologie und Tumor Microenvironment
- PD-1 und PD-L1 Expression in kutanen Neoplasien
- Prognosekriterien des malignen Melanoms
- Histologische Aufarbeitung und Beurteilung von Sentinel Lymphknoten

Mitgliedschaften:

- Arbeitsgemeinschaft für Dermatohistologie (ADH), 2. Vorsitzende seit Mai 2016
- International Society of Dermatopathology (ISDP) □
- American Society of Dermatopathology (ASDP)
- Deutsche Dermatologische Gesellschaft (DDG)
- Norddeutsche Dermatologische Gesellschaft (NDG) □
- European Academy of Dermatology and Venereology (EADV) □
- Deutsche Krebsgesellschaft □
- European Organization for Research and Treatment of Cancer (EORTC)
- International Society for Cutaneous Lymphoma (ISCL) □
- Arbeitsgemeinschaft dermatologische Onkologie (ADO) □
- Arbeitsgemeinschaft dermatologische Forschung (ADF) □
- Arbeitsgruppe kutane Lymphome der ADF □□

Ausgewählte Publikationen:

Lymphome und Pseudolymphome

1. **Mitteldorf C**, Grabbe S, Stadler R. WHO classification and clinical spectrum of cutaneous lymphomas. Hautarzt. 2017 Aug 22. doi: 10.1007/s00105-017-4025-1. [Epub ahead of print] Review.
2. **Mitteldorf C**, Kempf W. Cutaneous Pseudolymphoma. Surg Pathol Clin. 2017 Jun;10(2):455-476.
3. Kempf W, **Mitteldorf C**, Karai LJ, Robson A. Die histologischen Typen der lymphomatoiden Papulose - Ein Vorschlag für die Vereinfachung des Buchstabenchaos. J Dtsch Dermatol Ges. 2017 Apr;15(4):390-394.
4. Kempf W, **Mitteldorf C**. Pathologic Diagnosis of Cutaneous Lymphomas. Dermatol Clin. 2015 Oct;33(4):655-81.

5. Kempf W, Kazakov DV, Belousova IE, **Mitteldorf C**, Kerl K. Paediatric cutaneous lymphomas: a review and comparison with adult counterparts. *J Eur Acad Dermatol Venereol*. 2015 Sep;29(9):1696-709.
6. Kempf W, **Mitteldorf C**. Cutaneous lymphomas: new entities and rare variants. *Pathologe*. 2015 Feb;36(1):62-9.
7. Kempf W, Kazakov DV, **Mitteldorf C**. Cutaneous lymphomas: an update. Part 2: B-cell lymphomas and related conditions. *Am J Dermatopathol*. 2014 Mar;36(3):197-208.
8. **Mitteldorf C**, Robson A, Tronnier, M, Pfaltz MC, Kempf W. Galectin-3 expression in primary cutaneous CD30-positive lymphoproliferative disorders and transformed mycosis fungoides. *Dermatology*. 2015;231(2):164-70.
9. **Mitteldorf C**, Bertsch HP, Kaune KM, Krüger U, Klemke C-D, Neumann C. Hodgkin`s lymphoma in a patient effectively treated with bexarotene for mycosis fungoides. *J Eur Acad Dermatol Venerol* 2009; 23(5): 593-5.
10. **Mitteldorf C**, Tronnier M, Merz H, Hänßle H, Bertsch HP, Schön MP, Kaune KM. Insect-bite like reactions in a patient with B-CLL: FISH analysis revealed neoplastic B-cells in the skin infiltrate. *Br J Dermatol* 2012;167(4):944-6.
11. **Mitteldorf C**, Bertsch HP, Baumgart M, Haase D, Wulf G, Schön MP, Rosenwald A, Neumann C, Kaune KM. Lacking CD56 expression in a relapsing cutaneous blastic plasmacytoid dendritic cell neoplasm after allogeneic bone marrow transplantation: FISH analysis revealed loss of 11q. *J Eur Acad Dermatol Venerol*, 2011;25(10):1225-9.
12. **Mitteldorf C**, Bieri C, Wey N, Pfaltz M, Kutzner H, Roncador G, Tomasini D, Kempf W. Expression of PD-1 (CD279) in cutaneous B-cell lymphomas with correlation to lymphoma entities and biologic behavior. *Br J Dermatol*. 2013;169(6):1212-8.
13. **Mitteldorf C**, Stadler R, Bertsch HP, Neumann C. Folliculotropic mycosis fungoides with CD30+ large-cell transformation in a young woman: beneficial effect of bexarotene. *Br J Dermatol*. 2007;156: 584-6.
14. Buhl T, Bertsch HP, Kaune KM, **Mitteldorf C**, Schön MP, Kretschmer L. Low-dose gemcitabine efficacious in three patients with tumor-stage mycosis fungoides. *Clin Lymphoma Myeloma*. 2009; 9(5):E21-4.
15. Kaune KM, Baumgart M, Bertsch HP, **Mitteldorf C**, Müller-Hermelink HK, Haase D, Ghadimi BM, Schön MP, Neumann C. Solitary cutaneous nodule of blastic plasmacytoid dendritic cell neoplasm progressing to overt leukemia cutis after chemotherapy: immunohistology and FISH analysis confirmed the diagnosis. *Am J Dermatopathol*. 2009;31(7):695-701.
16. Kaune KM, Baumgart M, Gesk S, **Mitteldorf C**, Baesecke J, Glass B, Haase D, Siebert R, Ghadimi BM, Neumann C, Emmert S. Bullous Sweet's syndrome in a t(9;22)(q34;q11)-positive chronic myeloid leukemia patient treated with the

tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL-positive lesional cells. Arch Dermatol 2008; 144: 361-4.

17. Hallermann C, Kaune KM, Tiemann M, Kunze E, Griesinger F, **Mitteldorf C**, Bertsch HP, Neumann C; High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. Ann Hematol 2007;86: 509-15.

Tumor Microenvironment:

1. **Mitteldorf C**, Berisha A, Tronnier M, Pfaltz MC, Kempf W. PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma. J Cutan Pathol. 2017 Sep;44(9):740-746.
2. **Mitteldorf C**, Berisha A, Pfaltz MC, Broekaert SMC, Schön MP, Kerl K, Kempf W. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets. Am J Surg Pathol. 2017 Jul;41(7):998-1004.

Dermatohistologie:

1. Ottmann K, Tronnier M, **Mitteldorf C**. Detection of mitotic figures in thin melanomas--immunohistochemistry does not replace the careful search for mitotic figures in hematoxylin-eosin stain. J Am Acad Dermatol. 2015 Oct;73(4):637-44.
2. **Mitteldorf C**, Joest B, Tronnier M. Kutane kollagene Vaskulopathie - Remission der perivaskulären Depositionen nach Farbstofflasertherapie. J Dtsch Dermatol Ges. 2017 Sep;15(9):935-937.
3. **Mitteldorf C**, Rongioletti F, Kempf W, Tronnier M. Papular mucinosis with monotypic plasma cells in a child. J Eur Acad Dermatol Venereol. 2017 Feb;31(2):e89-e90.
4. **Mitteldorf C**, Tronnier M. Histologic features of granulomatous skin diseases. J Dtsch Dermatol Ges. 2016 Apr;14(4):378-88.
5. Tronnier M, **Mitteldorf C**. Histologic features of granulomatous skin diseases. Part 1: Non-infectious granulomatous disorders. J Dtsch Dermatol Ges. 2015 Mar;13(3):211-6.
6. **Mitteldorf C**, Palmedo G, Kutzner H, Kauer F, Prestin M, Schuster C, Hübscher E, Kirsch A, Tronnier, Kempf W. Diagnostic Approach in Lymphoplasmacytoid Plaque. JEADV. 2015;29(11):2206-15.
7. **Mitteldorf C**, Mertz KD, Fernández-Figueras MT, Schmid M, Tronnier M, Kempf W. Detection of Merkel cell Polyomavirus and human Papillomavirus in Merkel cell carcinoma combined with squamous cell carcinoma in immunocompetent European patients. Am J Dermatopathol. 2012; 34(5):506-10.

8. **Mitteldorf C**, Zelger B, Tronnier M. Sclerotic epithelioid Dermatofibroma. Am J Dermatopathol 2011; 33(1): 98-101.
9. Heineke A, Bendel M, Tronnier M, **Mitteldorf C**. Grouped papules on the left chest wall. J Dtsch Dermatol Ges. 2010; 8(9):715-7.

Sentinel Lymphknoten:

1. Kretschmer L, Bertsch HP, Zapf A, **Mitteldorf C**, Satzger I, Thoms KM, Völker B, Schön MP, Gutzmer R, Starz H. Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients. Medicine (Baltimore). 2015 Sep;94(36):e1433.
2. **Mitteldorf C**, Bertsch HP, Jung K, Thoms K-M, Schön MP, Tronnier M, Kretschmer L. Sentinel node biopsy improves prognostic stratification in patients with thin (pT1) melanomas and an additional risk factor Ann Surg Oncol 2014;21(7):2252-8.
3. Al Ghazal P, Gutzmer R, Satzger I, Starz H, Bader C, Thoms KM, **Mitteldorf C**, Schön MP, Kapp A, Bertsch HP, Kretschmer L. Lower prevalence of lymphatic metastasis and poorer survival of the sentinel node negative patients limit the prognostic value of sentinel node biopsy for head and neck melanomas. Melanoma Res. 2014, 24(2):158-64.
4. Kretschmer L, Sahlmann CO, Bardzik P, **Mitteldorf C**, Helms HJ, Meller J, Schön MP, Bertsch HP. Individualized surgery: gamma-probe-guided lymphadenectomy in patients with clinically enlarged lymph node metastases from melanomas. Ann Surg Oncol. 2013; 20(5):1714-21.
5. Kretschmer L, Starz H, Thoms KM, Satzger I, Völker B, Jung K, **Mitteldorf C**, Bader C, Siedlecki K, Kapp A, Bertsch HP, Gutzmer R. Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma. Int J Cancer. 2011 15; 129(6):1435-42.
6. **Mitteldorf C***, Bertsch HP*, Zapf A, Kretschmer L. Cutting a sentinel lymph node into slices is the optimal first step for examination of SLNs in melanoma patients. Mod Pathol. 2009; 22(12):1622-7.
7. Gutzmer R, Satzger I, Thoms KM, Völker B, **Mitteldorf C**, Kapp A, Bertsch HP, Kretschmer L. Der histologische Status des Sentinel Lymphknotens ist der wichtigste Prognosefaktor bei Melanomen ≥ 4 mm Tumordicke (Sentinel lymph node status is the most important prognostic factor for thick ($>$ or $= 4$ mm) melanomas.) J Dtsch Dermatol Ges 2008: 198-203.